The Retina Society 58th Annual Scientific Meeting
First-time results from the Phase 1b APEX Study evaluating the efficacy of a bispecific trap-antibody, KSI-101, in treating macular edema caused by inflammation in patients.
Bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor (KSI-101): first-time results from the Phase 1b APEX Study in patients with macular edema secondary to inflammation (MESI) Dolly Chang 1 ; Allen Hu 2 ; David Almeida 3 ; Scott Fitzpatrick 1 ; Victor Perlroth 1 ; J. Pablo Velazquez-Martin 1 1 Kodiak Sciences, Palo Alto, United States, 2 Cumberland Valley Retina Consultants, Hagerstown, United States, 3 Erie Retina Research, Erie, United States Relevant Financial Disclosures: Research with and Consultant for Kodiak Dr. Chang, Dr. Fitzpatrick, Dr. Perlroth and Dr. Velazquez-Martin are employees of Kodiak Sciences Charles C. Wykoff, M.D., Ph.D. Deputy Chair of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital Director of Research, Retina Consultants of Texas; Retina Consultants of America on behalf of the APEX Study Group
The Retina Society 58th Annual Scientific Meeting Page 2